FOOD: a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke

被引:3
|
作者
Dennis, M [1 ]
Lewis, S
Cranswick, G
Forbes, J
机构
[1] Univ Edinburgh, Div Clin Neurosci, Neurosci Trial Unit, Edinburgh EH8 9YL, Midlothian, Scotland
[2] Univ Edinburgh, Div Publ Hlth, Edinburgh EH8 9YL, Midlothian, Scotland
关键词
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To determine whether routine oral nutritional supplementation of a normal hospital diet improves outcome after stroke (Trial 1); whether early tube feeding improves the outcomes of dysphagic stroke patients (Trial 2); and if tube feeding via a percutaneous endoscopic gastrostomy (PEG) results in better outcomes than that via a nasogastric tube (NG) (Trial 3). Design: The Feed Or Ordinary Diet (FOOD) trial was a family of three pragmatic, randomised controlled trials (RCTs). They shared facilities for randomisation, data collection, follow-up and coordination. Patients could be co-enrolled in more than one of these trials. Setting: Patients were enrolled in 131 hospitals in 18 countries. Participants: A total of 5033 patients who had been admitted to hospital with a recent stroke were enrolled in the trials between November 1996 and July 2003. Interventions: In Trial 1, patients who could swallow within the first 30 days of admission were allocated to normal hospital diet versus normal hospital diet plus oral nutritional supplements (equivalent to 360 ml of 1.5 kcal/ml, 20 g of protein per day) until hospital discharge. In Trial 2, dysphagic patients enrolled within 7 days of admission were allocated to early enteral tube feeding versus avoid any enteral tube feeding for at least 1 week. In Trial 3, dysphagic patients were allocated within 30 days of admission to receive enteral tube feeding via PEG versus NG. Main outcome measures: Survival and the modified Rankin scale (MRS), a measure of functional outcome (grade 0 indicating no symptoms and grade 5 indicating severe disability, requiring help day and night). The primary outcomes were measured 6 months after enrolment, blind to treatment allocation, by the patient or their proxy completing a postal or telephone questionnaire. Results: In Trial 1, 4023 patients were enrolled by 125 hospitals in 15 countries. Only 314 (7.8%) patients were judged undernourished at baseline. Vital status and MRS at the end of the trial were known for 4012 (99.7%)and 4004 (99.5%), respectively. Of the 2007 allocated normal hospital diet, 253 (12.6%) died, 918 (45.7%) were alive with poor outcome (MRS 3-5) and 823 (41.1%) had a good outcome (MRS 0-2). Of the 2016 allocated oral supplements, 241 (12.0%) died, 953 (47.3%) were alive with poor outcome and 813 (40.4%) had a good outcome. The supplemented diet was associated with an absolute reduction in risk of death of 0.7% (95% CI -1.4 to 2.7; p = 0.5) and a 0.7% (95% CI -2.3 to 3.8, p = 0.6) increased risk of death or poor outcome. In Trial 2, a total of 859 patients were enrolled by 83 hospitals in 15 countries. MRS at the end of the trial was known for 858 (99.9%). At follow-up, of 429 allocated early tube feeding, 182 (42.4%) died, 157 (36.6%) were alive with poor outcome (MRS 4-5) and 90 (21.0%) had a good outcome (MRS 0-3). Of 430 allocated avoid tube feeding 207 (48.1%) died, 137 (31.9%) were alive with poor outcome and 85 (19.8%) had a good outcome. Early tube feeding was associated with an absolute reduction in risk of death of 5.8% (95% CI -0.8 to 12.5; p = 0.09) and a reduction in death or poor outcome of 1.2% (95% CI -4.2 to 6.6; p = 0.7). In Trial 3, 321 patients were enrolled by 47 hospitals in 11 countries. Of 162 allocated PEG, 79 (48.8%) died, 65 (40.1%) were alive with poor outcome and 18 (11.1%) had good outcome. Of 159 allocated NG, 76 (47.8%) died, 53 (33.3%) were alive with poor outcome and 30 (18.9%) had good outcome. PEG was associated with an increase in absolute risk of death of 1.0% (95% CI -10.0 to 11.9; p = 0.9) and an increased risk of death or poor outcome of 7.8% (95% CI 0.0 to 15.5; p = 0.05). Conclusions: The results of Trial 1 would be compatible with oral supplementation being associated with a 1-2% absolute benefit or harm, but do not support routine supplementation of hospital diet for unselected stroke patients who are predominantly well nourished on admission. In Trial 2, the data suggest that a policy of early tube feeding may substantially reduce the risk of dying after stroke and it is very unlikely that the alternative policy of avoiding early tube feeding would significantly improve survival. Improved survival may be at the expense of increasing the proportion surviving with poor outcome. These data might usefully inform the difficult discussions about whether or not to feed a patient with a severe stroke. In Trial 3, the data suggest that in the first 2-3 weeks after acute stroke, better functional outcomes result from feeding via NG tube than PEG tube, although there was no major difference in survival. These data do not support a policy of early initiation of PEG feeding in dysphagic stroke patients. Future research might be focused on making NG tube feeding safer and more effective, also studies need to confirm the increased risk of gastrointestinal haemorrhage associated with tube feeding and, if confirmed, establish whether any interventions might reduce this risk. Future work might also aim to establish why worse functional outcomes occurred in PEG-fed patients because patients with prolonged dysphagia or intolerance of an NG tube are inevitably fed via a PEG tube.
引用
收藏
页码:1 / +
页数:109
相关论文
共 50 条
  • [31] Predictors of Stroke Mortality among Patients Admitted to a Hospital in Ethiopia
    Gelan, Yohannes
    Weldeab, Amanuel
    NEUROLOGY, 2020, 94 (15)
  • [32] Bed ulcer in stroke patients admitted in hospital: A plight of Nepal
    Chandra, Ayush
    Chandra, Avinash
    Acharya, Sudikshya
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [33] Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial
    Zhao, Jingjing
    Yuan, Fang
    Song, Changgeng
    Yin, Rong
    Chang, Mingze
    Zhang, Wei
    Zhang, Bei
    Yu, Liping
    Jia, Yi
    Ma, Wiling
    Song, Yongbin
    Wang, Chengkai
    Song, Chaohui
    Wang, Xinfai
    Shang, Lei
    Yang, Fang
    Jiang, Wen
    LANCET NEUROLOGY, 2022, 21 (04): : 319 - 328
  • [34] The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial
    den Hertog, Heleen M.
    van der Worp, H. Bart
    van Gemert, H. Maarten A.
    Algra, Ate
    Kappelle, L. Jaap
    Van Gijn, Jan
    Koudstaal, Peter J.
    Dippel, Diederik W. J.
    LANCET NEUROLOGY, 2009, 8 (05): : 434 - 440
  • [35] A Very Early Rehabilitation Trial after stroke (AVERT): a Phase III, multicentre, randomised controlled trial
    Langhorne, Peter
    Wu, Olivia
    Rodgers, Helen
    Ashburn, Ann
    Bernhardt, Julie
    HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (54) : 1 - 119
  • [36] Integrative medicine for subacute stroke rehabilitation: a study protocol for a multicentre, randomised, controlled trial
    Fang, Jianqiao
    Chen, Lifang
    Chen, Luni
    Wang, Chao
    Keeler, Crystal Lynn
    Ma, Ruijie
    Xu, Shouyu
    Shen, Laihua
    Bao, Yehua
    Ji, Conghua
    BMJ OPEN, 2014, 4 (12):
  • [37] Focused ultrasound examination of the chest on patients admitted with acute signs of respiratory problems: a study protocol for a pragmatic randomised controlled multicentre trial
    Riishede, M.
    Laursen, C. B.
    Teglbjaerg, L. S.
    Lassen, A. T.
    Baatrup, G.
    BMJ OPEN, 2016, 6 (10):
  • [38] Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial
    Sivapalan, Pradeesh
    Lapperre, Therese S.
    Janner, Julie
    Laub, Rasmus R.
    Moberg, Mia
    Bech, Charlotte S.
    Eklof, Josefin
    Holm, Freja S.
    Armbruster, Karin
    Sivapalan, Praleene
    Mosbech, Christiane
    Ali, Aras K. M.
    Seersholm, Niels
    Wilcke, Jon T.
    Brondum, Eva
    Sonne, Tine P.
    Ronholt, Finn
    Andreassen, Helle F.
    Ulrik, Charlotte S.
    Vestbo, Jorgen
    Jensen, Jens-Ulrik S.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (08): : 699 - 709
  • [39] Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
    Lopes, Renato D.
    de Barros E Silva, Pedro Gabriel Melo
    Furtado, Remo H. M.
    Scarlatelli Macedo, Ariane Vieira
    Bronhara, Bruna
    Damiani, Lucas Petri
    Barbosa, Lilian Mazza
    Morata, Julia de Aveiro
    Ramacciotti, Eduardo
    Martins, Priscilla de Aquino
    de Oliveira, Aryadne Lyrio
    Nunes, Vinicius Santana
    Fonteles Ritt, Luiz Eduardo
    Rocha, Ana Thereza
    Tramujas, Lucas
    Santos, Sueli, V
    Abregu Diaz, Dario Rafael
    Viana, Lorena Souza
    Garcia Melro, Livia Maria
    de Alcantara Chaud, Mariana Silveira
    Figueiredo, Estevao Lanna
    Neuenschwander, Fernando Carvalho
    Andrade Dracoulakis, Marianna Deway
    Souza Dourado Lima, Rodolfo Godinho
    de Souza Dantas, Vicente Ces
    Silva Fernandes, Anne Cristine
    Eluf Gebara, Otavio Celso
    Hernandes, Mauro Esteves
    Rios Queiroz, Diego Aparecido
    Veiga, Viviane C.
    Canesin, Manoel Fernandes
    de Faria, Leonardo Meira
    Feitosa-Filho, Gilson Soares
    Gazzana, Marcelo Basso
    Liporace, Idelzuita Leandro
    Twardowsky, Aline de Oliveira
    Maia, Lilia Nigro
    Machado, Flavia Ribeiro
    Soeiro, Alexandre de Matos
    Conceicao-Souza, Germano Emilio
    Armaganijan, Luciana
    Guimaraes, Patricia O.
    Rosa, Regis G.
    Azevedo, Luciano C. P.
    Alexander, John H.
    Avezum, Alvaro
    Cavalcanti, Alexandre B.
    Berwanger, Otavio
    LANCET, 2021, 397 (10291): : 2253 - 2263
  • [40] Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
    Liu, Liping
    Xie, Xuewei
    Pan, Yuesong
    Wang, Aili
    Wei, Yufei
    Liu, Jingyi
    Nie, Ximing
    Liu, Dacheng
    Zhao, Zilin
    Wang, Penglian
    Shen, Suwen
    Zhong, Chongke
    Xu, Tan
    Wang, Dali
    Wang, Gui-Chun
    Song, Denghua
    Ma, Yunsheng
    Zhao, Jinguo
    Jiang, Yong
    Jing, Jing
    Meng, Xia
    Obst, Katherine
    Chen, Chung-Shiuan
    Wang, David
    Wang, Yilong
    Zhang, Yonghong
    Wang, Yongjun
    He, Jiang
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 383